lyophilized powder is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-01-16. Numbers and descriptions here follow the published literature rather than marketing material.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
== Mechanism of action == Immunoliposomes use similar functionality as liposomes with the added measure of conjugating monoclonal antibodies and their fragments to the liposomes. The use of antibodies allow for easy targeting as they can recognize many different types of antigens. Diseased cells typically contain more antigens than healthy cells, which is how antibodies are able to appropriately target certain extracellular domains (depending on antigen overexpression) and kill diseased cells. Liposomal drug delivery combined with antibodies as a targeting ligand are what help immunoliposomes function as an effective drug carrier.
==== 2000s ==== 2000 – First Medical Inc., Amelung GmbH, ARK Scientific 2001 – ISOTEC (produces stable isotopes used in basic research and medical diagnostics) 2004 – Ultrafine (a supplier of contract manufacturing services for drug development), Tetrionics (a producer of high potency and cytotoxic active pharmaceutical ingredients) 2005 – JRH Biosciences, an industrial supplier of cell culture products for the pharmaceutical and biotechnology industries; Proligo Group, a global supplier of genomics research tools 2006 – Beijing Superior Chemicals, Iropharm, Pharmorphix, Advanced Separation Technologies (manufacturer of products for chiral chromatography) 2007 – Epichem acquired to expand capabilities in materials sciences and semiconductor markets; Molecular Medicine BioServices acquired to provide large-scale viral manufacturing capabilities; announced alliance with Sangamo BioSciences to develop zinc finger-based laboratory research reagents 2009 – ChemNavigator 2010 – Cerilliant Corporation, ACE Animals 2011 – Resource Technology Corp, Vetec Quimica Fina 2012 – Research Organics Inc., BioReliance (a toxicology and veterinary diagnostics company); BioReliance had previously been acquired by Invitrogen and subsequently sold to Avista Capital Partners. 2014 – Cell Marque 2015 – Combined with EMD Millipore to make MilliporeSigma.
R6890, sometimes known as spirochlorphine, is an orphine opioid analgesic and a member of the spiropiperidine family of agents. The first known mention of this compound was in 1977. Other examples of agents from this class are Ro64-6198 and Ro65-6570. Brorphine also has a similar structure. It has been sold as a designer drug, and was proposed for placement on the Schedule 1 list in the USA on 1 July 2026. A precursor chemical used in the synthesis of R6890 is 1-phenyl-1,3,8-triazaspiro(4,5)decan-4-one (also known as spirodecanone), which is used in the synthesis of other drugs including spirilene, fluspirilene, spiramide, spiperone, RP-23618, spiroxatrine, L008716 and R5260.
Sources: en.wikipedia.org
Burning and itching sensations Throbbing pain Skin discoloration (red to dark blue) with erythema (blanchable redness) Blistering of affected area Ulceration (in severe cases only) Chilblains caused by exposure to cold and humidity usually heal within 7–14 days.
Apples have also been infected to a limited extent. Besides its pathogenic interactions, P. digitatum has been implicated in naturally accelerating the ripening of green fruits, and causing epinastic responses in various plants such as potato, tomato, and sunflowers.
==== Muslim Yibna, Early Islamic to Mamluk period ==== The Islamic historian al-Baladhuri (died 892 AD) describes Yibna as one of ten towns in Jund Filastin conquered by the Rashidun army led by 'Amr ibn al-'As in the early 7th century. Ibelin was first sacked by Saladin before his army was routed at the Battle of Montgisard in late 1177. In August 1187, it was retaken and burnt to the ground, and ceased for some time to form part of the Crusaders' kingdom.
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.